- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01336842
Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors
Phase I Trial of Cisplatin and Pemetrexed in Combination With Panobinostat in Advanced Solid Tumors, With Emphasis on Non-Small Cell Lung Cancer
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
California
-
Sacramento, California, Forenede Stater, 95817
- University of California Davis Cancer Center
-
-
Michigan
-
Detroit, Michigan, Forenede Stater, 48202
- Henry Ford Health System
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Histological or cytological proven advanced solid tumors for which curative standard treatments are not available.
- Must have measurable or evaluable disease.
- Male or female patients aged ≥ 18 years old.
- Any number of prior chemotherapy regimens.
- ECOG Performance Status of ≤ 2 with a life expectancy greater than 3 months.
- Clinically euthyroid (may be on thyroid hormone replacement)
- Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days of the first administration of study treatment.
- Ability to provide written informed consent
- Must meet the following laboratory criteria:
Hematology:
- Neutrophil count of ≥ 1.5 x 109/L
- Platelet count of ≥ 100 x 109/L
- Hemoglobin ≥ 9 g/dL
Biochemistry:
- AST/SGOT and ALT/SGPT ≤ 2.5 x upper limit of normal (ULN) or ≤ 5.0 x ULN if the transaminase elevation is due to disease involvement
- Serum bilirubin ≤ 1.5 x ULN
- Serum creatinine ≤ 1.5 x ULN or 24-hour creatinine clearance ≥ 50 ml/min
- Total serum calcium (corrected for serum albumin) or ionized calcium ≥ LLN and ≤ ULN
- Serum potassium ≥ LLN and ≤ ULN
- Serum sodium ≥ LLN and ≤ ULN
- Serum albumin ≥ LLN or 3g/dl
- Serum magnesium ≥ LLN and ≤ ULN
- Any elevated Alkaline Phosphatase due to bone metastasis can be enrolled
Exclusion Criteria:
- Prior HDAC, DAC, HSP90 inhibitors or valproic acid for the treatment of cancer.
- Patients who will need valproic acid for any medical condition during the study or within 5 days prior to first panobinostat treatment.
- Patients who have received chemotherapy, any investigational drug or undergone major surgery < 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy.
- Impaired cardiac function
- Other concurrent severe and/or uncontrolled medical conditions that could cause unacceptable safety risks or compromise compliance with the protocol
- Concomitant use of drugs which are generally recognized to have a risk of causing torsades de pointes where such treatment cannot be discontinued or switched to a different medication prior to starting study drug
- Patients with unresolved diarrhea ≥ CTCAE grade 2
- Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral panobinostat. Inability to swallow panobinostat capsules whole.
- Concomitant use of any anti-cancer therapy or radiation therapy
- Uncontrolled or symptomatic brain metastases.
- Women who are pregnant or breast feeding or women of childbearing potential (WOCBP) not willing to use a double barrier method of contraception during the study and 3 months after the end of treatment. One of these methods of contraception must be a barrier method. WOCBP are defined as sexually mature women who have not undergone a hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive months (i.e., who has had menses any time in the preceding 12 consecutive months).
- Male patients whose sexual partners are WOCBP not using a double method of contraception during the study and 3 months after the end of treatment.
- Known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required
- Any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Phase I dose-escalation
Drug: panobinostat Drug: cisplatin Drug: pemetrexed Other: Biomarker studies
|
Drug: Panobinostat Oral (by mouth) once daily every Monday, Wednesday, and Friday for the first two weeks of each three week cycle (as per dose escalation schedule (dose levels 1 and 2: AUC 5; dose levels 3 and 4: AUC 6). Number of cycles: 6 maximum. Drug: Cisplatin IV (in the vein) on day 1 of a 21-day cycle Number of cycles: 6 maximum. Drug: Pemetrexed IV (in the vein) on day 1 of a 21-day cycle Other: Correlative studies Biomarker Analysis: blood collected pre-study and Cycles 2-6, Day 1.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Safety and feasibility of oral panobinostat in combination with cisplatin and pemetrexed
Tidsramme: Within ±3 days of the scheduled day of assessment except for adverse events that will be evaluated continuously through the study. The expected time frame for this outcome measure is 18 weeks (or six cycles)
|
Safety assessments will consist of monitoring and recording all adverse events and serious adverse events, the regular monitoring of hematology, blood chemistry and urine values, regular measurement of vital signs and the performance of physical examination.
Safety and tolerability will be assessed according to the NCI CTCAE v4.
|
Within ±3 days of the scheduled day of assessment except for adverse events that will be evaluated continuously through the study. The expected time frame for this outcome measure is 18 weeks (or six cycles)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Maximum-tolerated dose as assessed by NCI CTCAE, Version 4.0
Tidsramme: 3 week cycle; the expected time frame is 18 weeks (or 6 cycles)
|
Determination of maximum tolerated dose (MTD) will be based on cycle 1 toxicities
|
3 week cycle; the expected time frame is 18 weeks (or 6 cycles)
|
Dose-limiting toxicities and toxicity profile as assessed by NCI CTCAE, Version 4.0
Tidsramme: 3 week cycle; the expected time frame is 18 weeks (or 6 cycles)
|
Dose-limiting toxicity (DLT) will be based on cycle 1 toxicities.
|
3 week cycle; the expected time frame is 18 weeks (or 6 cycles)
|
Exploratory biomarker analysis
Tidsramme: Blood specimens will be collected prior to treatment, prior to Cycles 2-6. In addition, a blood specimen will be collected if the patient is removed from the study due to progression of disease. the expected time frame is 18 weeks (or 6 cycles)
|
Molecular markers predictive for response to panobinostat remain unknown.
This trial offers the opportunity to retrospectively study biomarkers and their association with clinical outcomes.
|
Blood specimens will be collected prior to treatment, prior to Cycles 2-6. In addition, a blood specimen will be collected if the patient is removed from the study due to progression of disease. the expected time frame is 18 weeks (or 6 cycles)
|
Efficacy of oral panobinostat in combination with cisplatin/pemetrexed in an expanded cohort of patients with NSCLC
Tidsramme: CT scans will be performed at baseline and every two cycles; the expected time frame is 18 weeks (or 6 cycles)
|
Response rate will be assessed by CT scan.
CT scans will be performed at baseline and every two cycles.
The evaluation of response will be based on standard RECIST criteria.
|
CT scans will be performed at baseline and every two cycles; the expected time frame is 18 weeks (or 6 cycles)
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: David Gandara, MD, University of California, Davis
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Luftvejssygdomme
- Neoplasmer
- Lungesygdomme
- Neoplasmer efter sted
- Neoplasmer i luftvejene
- Thoracale neoplasmer
- Karcinom, bronkogent
- Bronkiale neoplasmer
- Lungeneoplasmer
- Karcinom, ikke-småcellet lunge
- Molekylære mekanismer for farmakologisk virkning
- Nukleinsyresyntesehæmmere
- Enzymhæmmere
- Antineoplastiske midler
- Folinsyreantagonister
- Histon deacetylase hæmmere
- Pemetrexed
- Panobinostat
Andre undersøgelses-id-numre
- UCDCC#220
- 222274 (Anden identifikator: UC Davis)
- CLBH589BUS31T (Anden identifikator: Novartis)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Faste tumorer
-
Memorial Sloan Kettering Cancer CenterRekrutteringSolid tumor | Solid tumor, voksen | Solid tumor, uspecificeret, voksenForenede Stater
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRekrutteringSolid tumor | Solid tumor, voksen | Solid tumor, uspecificeret, voksenForenede Stater, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRekrutteringSolid tumor | Solid tumor, voksen | Solid tumor, uspecificeret, voksenForenede Stater, Puerto Rico
-
Sorrento Therapeutics, Inc.Trukket tilbageSolid tumor | Recidiverende solid tumor | Refraktær tumor
-
BeiGeneRekrutteringSolid tumor | Avanceret solid tumorForenede Stater, New Zealand, Australien, Kina
-
Anjali PawarRekrutteringSolid tumor | Solid tumor, barndomForenede Stater
-
Impact Therapeutics, Inc.RekrutteringSolid tumor | Avanceret solid tumorKina, Taiwan, Forenede Stater, Australien
-
Partner Therapeutics, Inc.Trukket tilbageSolid tumor | Solid tumor, voksenForenede Stater
-
Novartis PharmaceuticalsAfsluttetKræft | Solid tumor | Avanceret solid tumorJapan
-
Pyxis Oncology, IncRekrutteringSolid tumor | Avanceret solid tumorForenede Stater, Spanien, Belgien
Kliniske forsøg med Panobinostat, Cisplatin, Pemetrexed
-
CanBas Co. Ltd.AfsluttetFaste tumorer | Malignt pleura mesotheliomForenede Stater
-
CanBas Co. Ltd.AfsluttetMetastatisk ikke-pladeepitel, ikke-småcellet lungekræftForenede Stater
-
BayerAfsluttet
-
PfizerAfsluttetNSCLC (ikke-småcellet lungekræft)Hong Kong, Kina, Taiwan, Malaysia, Thailand
-
Yonsei UniversityAktiv, ikke rekrutterendeSarkomKorea, Republikken
-
Eli Lilly and CompanyAfsluttetGastrointestinale neoplasmerKorea, Republikken
-
BeiGeneAfsluttet
-
Yonsei UniversityRekruttering
-
Eli Lilly and CompanyAfsluttetMalignt pleura mesotheliomJapan
-
Cancer Trials IrelandTrukket tilbage